Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes.
Buccisano F, Maurillo L, Tamburini A, Del Poeta G, Del Principe MI, Ammatuna E, Consalvo MI, Campagna S, Ottaviani L, Sarlo C, Renzi D, Faccia S, Fraboni D, Lo Coco F, Amadori S, Venditti A. Buccisano F, et al. Among authors: ottaviani l. Eur J Haematol. 2008 Feb;80(2):107-14. doi: 10.1111/j.1600-0609.2007.00986.x. Epub 2007 Nov 17. Eur J Haematol. 2008. PMID: 18028430
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia.
Buccisano F, Maurillo L, Gattei V, Del Poeta G, Del Principe MI, Cox MC, Panetta P, Consalvo MI, Mazzone C, Neri B, Ottaviani L, Fraboni D, Tamburini A, Lo-Coco F, Amadori S, Venditti A. Buccisano F, et al. Among authors: ottaviani l. Leukemia. 2006 Oct;20(10):1783-9. doi: 10.1038/sj.leu.2404313. Epub 2006 Jul 13. Leukemia. 2006. PMID: 16838027
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia.
Del Principe MI, Del Poeta G, Buccisano F, Maurillo L, Venditti A, Zucchetto A, Marini R, Niscola P, Consalvo MA, Mazzone C, Ottaviani L, Panetta P, Bruno A, Bomben R, Suppo G, Degan M, Gattei V, de Fabritiis P, Cantonetti M, Lo Coco F, Del Principe D, Amadori S. Del Principe MI, et al. Among authors: ottaviani l. Blood. 2006 Aug 1;108(3):853-61. doi: 10.1182/blood-2005-12-4986. Epub 2006 Apr 6. Blood. 2006. PMID: 16601244 Free article.
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Maurillo L, Buccisano F, Spagnoli A, Del Poeta G, Panetta P, Neri B, Del Principe MI, Mazzone C, Consalvo MI, Tamburini A, Ottaviani L, Fraboni D, Sarlo C, De Fabritiis P, Amadori S, Venditti A. Maurillo L, et al. Among authors: ottaviani l. Haematologica. 2007 May;92(5):605-11. doi: 10.3324/haematol.10432. Haematologica. 2007. PMID: 17488683 Free article.
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
Maurillo L, Buccisano F, Del Principe MI, Del Poeta G, Spagnoli A, Panetta P, Ammatuna E, Neri B, Ottaviani L, Sarlo C, Venditti D, Quaresima M, Cerretti R, Rizzo M, de Fabritiis P, Lo Coco F, Arcese W, Amadori S, Venditti A. Maurillo L, et al. Among authors: ottaviani l. J Clin Oncol. 2008 Oct 20;26(30):4944-51. doi: 10.1200/JCO.2007.15.9814. Epub 2008 Jul 7. J Clin Oncol. 2008. PMID: 18606980 Free article.
Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia.
Buccisano F, Maurillo L, Spagnoli A, Del Principe MI, Fraboni D, Panetta P, Ottone T, Consalvo MI, Lavorgna S, Bulian P, Ammatuna E, Angelini DF, Diamantini A, Campagna S, Ottaviani L, Sarlo C, Gattei V, Del Poeta G, Arcese W, Amadori S, Lo Coco F, Venditti A. Buccisano F, et al. Among authors: ottaviani l. Blood. 2010 Sep 30;116(13):2295-303. doi: 10.1182/blood-2009-12-258178. Epub 2010 Jun 14. Blood. 2010. PMID: 20548095 Free article. Clinical Trial.
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy.
Sarlo C, Buccisano F, Maurillo L, Cefalo M, Di Caprio L, Cicconi L, Ditto C, Ottaviani L, Di Veroli A, Del Principe MI, Grasso MA, Nasso D, De Santis G, Amadori S, Venditti A. Sarlo C, et al. Among authors: ottaviani l. Leuk Res Treatment. 2013;2013:705714. doi: 10.1155/2013/705714. Epub 2013 Apr 28. Leuk Res Treatment. 2013. PMID: 23738080 Free PMC article.
58 results